Related Experiment Video
Updated: May 24, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
[Associations between candidate genes with schizophrenia susceptibility and the treatment efficiency]
Piotr Tybura1, Anna Grzywacz, Agnieszka Samochowiec
1Katedra i Klinika Psychiatrii PAM w Szczecinie.
Aim:
The aim of the study was to find genetic markers which can have influence on susceptibility of paranoid schizophrenia and the treatment efficiency measured by the PANSS (Positive and Negative Syndrome Scale). We analysed the gene polymorphisms: dopamine receptor--DRD2 (Taq 1A, in egzon 8,- 141 C ins/del), dopamine transporter--DAT, kainate receptor--GRIK3, serotonine transporter--SERT, serotonine receptor--5HT2A, mono amine oxidase A--MAO-A, catechol O-methyl transferase--COMT.
Method:
One hundred four Polish patients with the diagnosis of paranoid schizophrenia were recruited as the study group. To obtain the diagnosis meeting the ICD-10 criteria, we used the Polish version of CIDI--Composite International Diagnostic Interview. Exclusion criteria included serious neurological disorders, major somatic disorders impairing cognitive functions and diagnosed mental impairment. The intensity of psychopathological symptoms was examined using the PANSS. Genomic DNA was extracted from leucocytes using the Miller's salting method. Polymorphisms were studied by the PCR (Polymerase Chain Reaction) method using RFLP (Restriction Fragments Length Polymorphism) and VNTR (Variable Number Tandem Repeat) technique. Statistical analyses were performed by the Statistica computer program, specifically Pearson's chi-square test. Associations between the treatment progress and the genotype were studied by analysis of variance (ANOVA).
Results:
We did not find associations between investigated gene polymorphisms and susceptibility of paranoid schizophrenia. Probably, there is no influence of studied polymorphisms on the treatment efficiency.
Conclusions:
No differences were found in the genotypes distribution in the studied gene polymorphisms between the whole schizophrenics and the control group. No association was found between any particular genotype and the effect of antipsychotic treatment.
More Related Videos
08:04Derivation, Expansion, Cryopreservation and Characterization of Brain Microvascular Endothelial Cells from Human Induced Pluripotent Stem Cells
Published on: November 19, 2020
05:51A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
Published on: June 15, 2011
Related Concept Videos
Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...